New Study Details Implementation Process for BETR-D Randomized Clinical Trial on UVC Disinfection

Posted by Tru-D SmartUVC 02.05.18

A recent paper has been published detailing the implementation process of the Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study, the first and only randomized clinical trial on UVC disinfection. The new report, Implementation Lessons Learned From the Benefits of Enhanced Terminal Room (BETR) Disinfection Study: Process and Perceptions of Enhanced Disinfection with Ultraviolet Disinfection Devices, was recently published in Infection Control and Hospital Epidemiology. Among the key items discussed are logistic and administrative processes utilized during the trial and lessons learned that are pertinent to future utilization of UVC disinfection devices in other hospitals.

“The study implementation protocols mirror the messaging and program management process that Tru-D currently uses with our hospital partners,” said Alice Brewer, Clinical Affairs Director for Tru-D SmartUVC. “In order for a hospital to implement a successful UVC disinfection program, there must be good communication, a focus on patient safety, compliance tracking and appropriate resource allocation.”

The BETR-D study aimed to disinfect all contact precaution rooms; during the 28-month trial, Tru-D was deployed in 16,220 of 18,411 eligible contact precaution rooms with the median hospital compliance against contact precaution rooms being 89 percent (86 percent-92 percent). In order to achieve this high level of compliance, the authors urge environmental services leadership to work with infection prevention and bed control departments to ensure that enhanced strategies are prioritized in appropriate rooms.

In addition, the authors noted that administrative leaders are often conflicted on whether or not to use UV disinfection due to the need to promptly admit patients waiting in the emergency department or waiting area.  The study authors stated, “We believe that this conflict needs to be viewed as a safety issue because enhanced disinfection using UV devices is an evidence-based strategy to improve patient safety.” The authors further explained that when they tracked the amount of time required to bring a patient to a room labeled as ‘under pressure’ they observed that, “In our experience, this pressure was related more to perception than an actual barrier to use of the UV device…there was always sufficient time to run a standard UV device cycle.”

The BETR-D study was a 28-month, cluster randomized, multicenter crossover study that was conducted from 2012-2014 across nine hospitals in the Duke Infection Control Outreach Network. Tru-D was the only device chosen for the CDC-funded study due to its ability to establish a baseline of disinfection and eliminate human error in the disinfection process. Results showed that enhanced terminal room disinfection strategies using Tru-D decreased the relative risk of colonization and infection of target MDROs among patients admitted to the same room by a cumulative 30 percent in a hospital setting with 93 percent compliance of standard disinfection protocols. Individual hospital results may vary.

Tru-D pioneered the UVC disinfection industry which has grown exponentially in recent years. Used in conjunction with manual cleaning, Tru-D is deployed after the environmental services staff cleans the room with traditional protocols. Activated by a remote control outside the room, Tru-D then administers one cycle of UVC energy from one, central placement in the room. Once the cycle is complete, the operator is notified via audio and/or text message that Tru-D can be moved to the next room.  In addition to the BETR-D study, Tru-D’s technology has been validated by fifteen other independent, third-party studies.

For more information on Tru-D’s technology and/or to watch a video on the power of one placement and one cycle, visit tru-dpowerofone.com.

Posted 02.05.18
  • Share

Never miss the latest in UV news.
Subscribe to UVC360 today.

Sign Up »